Digestive disorders classify diseases that typically affect the gastrointestinal (GI) tract which also includes the colon and rectum; these diseases can be as common as Irritable Bowel Syndrome (IBS) or a rare condition like Crohn’s disease. Several factors can contribute damage to the GI tract and impede its ability to work correctly - a low fiber diet, lack of exercise, stress, an excess of dairy intake, particular medications and even antacids to name a few. Conventional prevention of digestive diseases includes healthy eating habits, regular bowel movements and routine screenings .
Cannabinoid Receptors Within (GI) Tract
Over the years, science has recognized the potential of cannabinoids to regulate gastrointestinal inflammation; records indicate cannabinoid compounds were mitigating symptoms like diarrhea and abdominal cramping, but many therapeutic effects from cannabinoids have not yet become mainstream. Studies have published reviews on the presence and capabilities of the cannabinoid (CB2) receptors located in the GI tract which suggests immunomodulatory functions within inflammatory systems without any psychotropic side effects .
Research articles highlight how stimulating CB2 receptors in the GI tract with cannabinoids like CBD can restrict abdominal pain and ventral sensitivity, adjust intestinal inflammation, and manage motility dysfunction. Results describe CB2 receptors as a viable apparatus to target inflammation and its symptoms and implies CB2 activation as a natural form of therapy for gastrointestinal disorders involving abnormal motility and immune stimulation .